Parexel at hold by Jefferies

Parexel International was maintained at a hold rating and a $25 price target by Jefferies & Co., Inc. analyst David Windley after reports that six patients suffered serious adverse side effects after being injected with the compound TGN 1412 during a phase 1 study being conducted in the United Kingdom. Shares of the Waltham, Mass., biopharmaceutical company were down $1.62, or 6.28%, at $24.17 on volume of 709,166 shares versus the three-month running average of 180,241 shares. (Nasdaq: PRXL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.